Abbott park
ABBOTT PARK, Illinois and IRVING, Texas, December 12, 2011 -
- Agreement Calls for 50/50 Global Profit Share for Multiple New Molecules
- Companies Plan to Explore Broad Therapeutic Potential of AIM Class
Abbott (NYSE: ABT) and Reata Pharmaceuticals today announced that they have entered into a worldwide collaboration to jointly develop and commercialize Reata's portfolio of second-generation oral antioxidant inflammation modulators (AIMs).
ABBOTT PARK, Illinois, December 9, 2011 -
The board of directors of Abbott (NYSE: ABT)today declared a quarterly common dividend of 48 cents per share.
ABBOTT PARK, Illinois, December 8, 2011 -
Abbott (NYSE: ABT) today announced the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial to evaluate the safety, efficacy and performance of the Absorb™ bioresorbable vascular scaffold (BVS) compared to the company's XIENCE PRIME™ Everolimus Eluting Coronary Stent System.
ABBOTT PARK, Illinois, November 14, 2011 -
-- Long-Term Clinical Results for the Investigational ABSORB Device are Consistent with Earlier Reported Data in the ABSORB Trial
-- Low Late Loss of 0.27 mm at Two Years; Comparable to Results Seen at One Year
-- Two-Year Imaging Results Show the Vessel Remains Open without the Need for Scaffold Support
Abbott (NYSE: ABT) today announced positive long-term data from the two-stage ABSORB trial, which is evaluating the ABSORB drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease.
ABBOTT PARK, Illinois, November 9, 2011 -
- New Highly Sensitive Hepatitis Test Detects Mutant Virus Strains
Abbott announced it has received CE Marking (Conformit Europenne) in the European Union to market a new, highly sensitive diagnostic test for detection of hepatitis B surface antigen (HBsAg).
More News
- Abbott Presents HUMIRA (Adalimumab) Phase 3 Study Results for Patients with Active Non-Radiographic Axial Spondyloarthritis
- Abbott Announces New Long-Term Data Evaluating Use of HUMIRA (Adalimumab) for Patients with Long-Standing Moderate to Severe Rheumatoid Arthritis and for Patients with Early Moderate to Severe RA
- Abbott to Present New Data for Key Vascular Products at TCT 2011
- Abbott to Present Broad Spectrum of Compelling Data for HUMIRA (Adalimumab) at American College of Rheumatology Annual Scientific Meeting
- Abbott Receives U.S. FDA Approval for Next-Generation XIENCE PRIME Drug Eluting Stent
- Abbott Reports Strong Ongoing Third Quarter Results; Confirms Double-Digit Ongoing Earnings Growth Outlook for 2011
- Abbott to Separate into Two Leading Companies in Diversified Medical Products and Research-Based Pharmaceuticals
- Abbott’s ABSORB Bioresorbable Vascular Scaffold Honored with Wall Street Journal Technology Innovation Award
- Abbott Enrolls First U.S. Patient in Global EXCEL Trial Comparing XIENCE to Coronary Artery Bypass Surgery
- Abbott Named Top Dealmaker for Fourth Consecutive Year by The Deal
- Abbott Declares 351st Consecutive Quarterly Dividend
- Abbott Initiates International ABSORB BTK Clinical Trial for Treatment of Below-the-Knee Critical Limb Ischemia
- First Patient in Japan Treated with Abbott’s Bioresorbable Vascular Scaffold as Part of Global Clinical Trial
- Abbott Expanding Manufacturing Capacity in China to Meet Demands of Fast-Growing Nutrition Market
- Abbott Reports 11 Percent Ongoing Earnings-Per-Share Growth in Second Quarter; Raises 2011 EPS Guidance Range
- Abbott Confirms Long-Term Commitment to HIV Care with the Planned Development of New Formulations
- Abbott and Biotest Announce Global Agreement to Develop and Commercialize Novel Antibody for Autoimmune Diseases
- Abbott Declares 350th Consecutive Quarterly Dividend
- Abbott Receives U.S. FDA Approval for XIENCE nano(TM) to Treat Coronary Artery Disease in Small Vessels
- Expanded Indication Supported by Results from the CREST Trial, Which Demonstrated Similar Safety and Efficacy for Stenting and Surgery
- Abbott Highlights Top-Tier Financial Performance, Strong Growth in Emerging Markets at Annual Meeting
- Abbott Reports 17.4 Percent Sales Growth and 12.3 Percent Ongoing Earnings-Per-Share Growth in First Quarter
- Abbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data From Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
- Abbott Announces Crohn's Disease Trial to Explore Benefit of New Therapeutic Monitoring Parameters for Patients
- First-of-its-Kind, Minimally Invasive Treatment Option for Select Patients
- Abbott to Present Data on Novel Vascular Technologies and XIENCE V(R) at ACC 2011
- Company's Philanthropic Foundation the Abbott Fund Provides $3 Million to Help People Affected by the Earthquake and Tsunami
- Company Declares 349th Consecutive Quarterly Dividend
- With Previous CE Mark in Europe, the TREK Balloon Dilatation Catheter System is Now Available in All Major Markets Worldwide
- Abbott Reports Double-Digit Sales and Ongoing Earnings Growth in Fourth Quarter; Issues Strong Ongoing Earnings Outlook for 2011
- FDA Advisory Committee Votes Favorably on Expanding the Indication for Abbott's Carotid Stent System to Include Patients at Standard Surgical Risk
- New Abbott Vitamin D Test Available for Use in the European Union
- Abbott's Newest Innovation Can Treat a Patient's Blocked Heart Vessel and Then Dissolve, Leaving the Patient's Vessel Free of a Permanent Metallic Implant
- EpiTherapeutics and Abbott Enter Into Oncology Collaboration on Epigenetic Targets
- Abbott Announces Positive Results from Phase 2 Study of Low Dose Atrasentan for Treatment of Diabetic Kidney Disease
